Acute migraine: novel therapy shows promise in Phase III trial

Written by Sharon Salt, Editor

A drug that belongs to a new generation of acute migraine treatments, termed rimegepant, has been demonstrated to eliminate pain and reduce bothersome symptoms for people with migraine in a randomized, double-blind, large-scale trial. At present, many individuals with migraine take triptan drugs, which work by stimulating serotonin receptors to reduce inflammation and constrict blood vessels. However, triptans can produce intolerable side effects in some individuals, particularly those with cardiovascular disease or associated major risk factors. Thus, a new class of drugs that target CGRP receptors called gepants, which includes rimegepant, may be more beneficial. In this new study, which...

To view this content, please register now for access

It's completely free